1. Home
  2. GERN vs EVER Comparison

GERN vs EVER Comparison

Compare GERN & EVER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.31

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo EverQuote Inc.

EVER

EverQuote Inc.

HOLD

Current Price

$19.35

Market Cap

928.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
EVER
Founded
1990
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
928.5M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
GERN
EVER
Price
$1.31
$19.35
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$2.17
$27.00
AVG Volume (30 Days)
8.8M
544.7K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
51.85
198.86
EPS
N/A
1.04
Revenue
$1,065,000.00
$163,349,000.00
Revenue This Year
$26.91
$14.73
Revenue Next Year
$43.75
$11.51
P/E Ratio
N/A
$21.95
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$13.88
52 Week High
$2.01
$28.73

Technical Indicators

Market Signals
Indicator
GERN
EVER
Relative Strength Index (RSI) 39.30 27.65
Support Level $1.24 $14.40
Resistance Level $1.32 $20.17
Average True Range (ATR) 0.07 1.20
MACD -0.02 -0.41
Stochastic Oscillator 10.00 0.59

Price Performance

Historical Comparison
GERN
EVER

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About EVER EverQuote Inc.

EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.

Share on Social Networks: